Becker Muscular Dystrophy - Pipeline Review, H1 2019 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Apr 5, 2019--The “Becker Muscular Dystrophy - Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Becker Muscular Dystrophy - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Becker Muscular Dystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Becker Muscular Dystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Becker Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 2 and 1 respectively.
Becker Muscular Dystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Becker Muscular Dystrophy (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Becker Muscular Dystrophy (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Becker Muscular Dystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Becker Muscular Dystrophy (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Becker Muscular Dystrophy (Genetic Disorders)
Key Topics Covered:
- Report Coverage
- Becker Muscular Dystrophy - Overview
- Becker Muscular Dystrophy - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Becker Muscular Dystrophy - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
Becker Muscular Dystrophy - Companies Involved in Therapeutics Development
- Catabasis Pharmaceuticals Inc
- Italfarmaco SpA
- Milo Biotechnology LLC
- PTC Therapeutics Inc
- ReveraGen BioPharma Inc
Becker Muscular Dystrophy - Drug Profiles
- ARM-210 - Drug Profile
- ataluren - Drug Profile
- edasalonexent - Drug Profile
- epicatechin - Drug Profile
- givinostat - Drug Profile
- vamorolone - Drug Profile
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/gprkq0
View source version on businesswire.com:https://www.businesswire.com/news/home/20190405005183/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Central Nervous System Drugs ,Musculoskeletal Disorders Drugs
INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 04/05/2019 08:07 AM/DISC: 04/05/2019 08:07 AM